Abstract 367P
Background
MET amplification is a rare genetic mutation which can be treated with small-molecule inhibitor-crizotinib. Based on the detection of next-generation sequencing, the molecular characteristics and the efficacy of crizotinib among different subsets of MET amplification in lung cancer patients is poorly understood.
Methods
From January 2018 to April 2019, patients with MET amplification detected by next-generation sequencing were retrospectively collected and the efficacy of crizotinib among different subsets of patients were analyzed.
Results
In our study, 4.16% (112/2694) patients were found to have MET amplification and only 19 patients treated with monotherapy crizotinib. Among the 112 MET amplification patients, primary (with or without other mutation) MET amplification accounted for 3.27% (82/2507) and 16.04% (30/187) re-biopsy patients were found to have acquired MET amplification after the failed treatment of EGFR-TKI. The frequency of MET amplification combined with EGFR 21L858R was slightly higher than that of MET amplification combined with EGFR 19 del (primary or acquired). Primary MET amplification can occur simultaneously with EGFR 20ins or ALK rearrangement. In survival analysis, the median PFS of 10 patients with copy number greater than 4 (CN > 4) seems longer than the nine patients with copy number less than or equal to 4 (CN ≤ 4) (4.7 months vs 2.7 months) and the two curves were separate, but failed to get a statistical significance (p = 0.085). No significant difference has been discovered between the median PFS of primary (4.04 months; 95%CI: 0.33-7.74 months) and acquired (2.99 months; 95% CI: 2.51-3.47 months; P = 0.382) MET amplification.
Conclusions
4.16% lung cancer patients were found to have MET amplification based on the detection of NGS. MET amplification patients treated with crizotinib with copy number greater than 4 (CN > 4) seem have longer PFS. No obvious survival difference has been discovered between primary and acquired MET amplification.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
97P - The role of adjuvant chemotherapy according to the status of surgical margin in rectal cancer
Presenter: Jong Hoon Lee
Session: Poster display session
Resources:
Abstract
98P - Influence of DPYD*9, DPYD*6 and GSTP1 ile105val genetic polymorphisms on capecitabine and oxaliplatin (CAPOX) associated toxicities in colorectal cancer patients
Presenter: Ashok Varma
Session: Poster display session
Resources:
Abstract
99P - Patient-derived tumour model by new culture method leading to the precision medicine
Presenter: Norikatsu Miyoshi
Session: Poster display session
Resources:
Abstract
100P - Clinical impact and carcinogenic mechanism of NCAPG overexpression in colon cancer
Presenter: Kai-Yuan Lin
Session: Poster display session
Resources:
Abstract
101P - Combined cellular immunotherapy and chemotherapy improves clinical outcome and displays safety in the treatment of patients with colorectal cancer
Presenter: Chang Wang
Session: Poster display session
Resources:
Abstract
102P - Clinical features of anorectal cancer in patients with Crohn’s disease: Japanese single center study
Presenter: Kazuhiro Watanabe
Session: Poster display session
Resources:
Abstract
103P - Contrast-enhanced CT-based textural parameters as potential prognostic factors of survival for colorectal cancer patients receiving targeted therapy
Presenter: Yanfei Yang
Session: Poster display session
Resources:
Abstract
104P - Prognostic significance of tumour location to the oncologic outcome of colon cancer
Presenter: Sare Hosseini
Session: Poster display session
Resources:
Abstract
105P - Detection and clinical significance of circulating tumour cells in patients with rectal cancer
Presenter: Shuohui Dong
Session: Poster display session
Resources:
Abstract
106P - The risk of malignization incidence in patients with polyps and polyposis of the colon and rectum
Presenter: Yakov Ten
Session: Poster display session
Resources:
Abstract